Skip to content
About HeartSciences

Healthcare information technology for the heart.

HeartSciences (Nasdaq: HSCS / HSCSW) is advancing the use of ECG/EKG through the integration of artificial intelligence — building a device-agnostic, next-generation ECG management system that simplifies clinical workflows.

Our mission

Earlier detection. Better outcomes.

Most patients with heart disease are asymptomatic. Front-line clinicians have limited tools to detect it early. We're applying modern AI to the world's most widely-used cardiac diagnostic to close that gap — without forcing anyone to change how they work.

2014

Founded in Southlake, TX

Nasdaq

HSCS · HSCSW

ISO 13485

Certified

Leadership

The team behind HeartSciences.

AS

Andrew Simpson

Chairman & CEO

MH

Mark Hilz

Chief Operating Officer

DW

Danielle Watson

Chief Financial Officer

AP

Aaron Peterson

VP, Research & Development

IS

Isabella Schmitt

VP, Clinical & Regulatory Affairs

GG

Gene Gephart

Director of Marketing

Scientific advisory board

Cardiologists and AI researchers shaping the work.

PP

Partho P. Sengupta, MD

Rutgers Robert Wood Johnson · SAB Chair

JN

Jagat Narula, MD, PhD

Mount Sinai Heart

GN

Girish Nadkarni, MD, MPH

Mount Sinai

AV

Akhil Vaid, MBBS

Mount Sinai · Data Science

JL

Joshua Lampert, MD

Mount Sinai · Cardiology

BG

Ben Glicksberg, PhD

Mount Sinai · AI Research

JS

Jordan Strom, MD, MSc

Beth Israel Deaconess

Company

The journey so far.

  1. 2014

    HeartSciences founded

    Incorporated in Southlake, Texas with a vision of applying AI to the standard ECG.

  2. 2017

    wavECG developed

    First-generation MyoVista wavECG device built on continuous wavelet transform signal processing.

  3. 2019

    First clinical studies

    Initiated multi-site research partnerships with academic medical centers.

  4. 2021

    Nasdaq listing

    Listed on Nasdaq (HSCS / HSCSW), capitalizing the platform build-out.

  5. 2022

    Mount Sinai license agreements

    Licensed AI cardiovascular algorithm IP from the Icahn School of Medicine at Mount Sinai.

  6. 2024

    FDA Breakthrough Designation

    AI-ECG algorithm for aortic stenosis received FDA Breakthrough Device Designation.

  7. 2025

    MyoVista Insights v1.1

    Major usability upgrade shipped; FDA 510(k) submission filed for the wavECG device.

  8. 2026

    Cibolo Health partnership

    MyoVista Insights endorsed across a 123-hospital independent network in six states.

Join us

Partner with HeartSciences.

Whether you're a clinician, health system, or researcher — we'd like to hear from you.

Request demo View clinical evidence